KR920012031A - 헤테로고리 화합물 - Google Patents

헤테로고리 화합물 Download PDF

Info

Publication number
KR920012031A
KR920012031A KR1019910022609A KR910022609A KR920012031A KR 920012031 A KR920012031 A KR 920012031A KR 1019910022609 A KR1019910022609 A KR 1019910022609A KR 910022609 A KR910022609 A KR 910022609A KR 920012031 A KR920012031 A KR 920012031A
Authority
KR
South Korea
Prior art keywords
methylbenzenesulfonamide
methoxybenzoyl
indol
ylmethyl
amino
Prior art date
Application number
KR1019910022609A
Other languages
English (en)
Other versions
KR100194479B1 (ko
Inventor
파울 에드워즈 마틴
데이비드 셔우드 죤
Original Assignee
수잔 제인 젠틀
임페리얼 케미칼 인더스트리스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수잔 제인 젠틀, 임페리얼 케미칼 인더스트리스 피엘씨 filed Critical 수잔 제인 젠틀
Publication of KR920012031A publication Critical patent/KR920012031A/ko
Application granted granted Critical
Publication of KR100194479B1 publication Critical patent/KR100194479B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

헤테로고리 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 N-[4-[5-(시클로펜틸옥시카르보닐)아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 형태 X의 적외선 스펙트럼, 제2도는 N-[4-[5-(시클로펜틸옥시카르보닐)아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 형태 A의 적오선 스펙트럼, 제3도는 N-[4-[5-(시클로펜틸옥시카르보닐)아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 형태 B의 적외선 스펙트럼.

Claims (7)

  1. 2θ=8.1, 13.7, 16.4, 20.5 및 23.7°에서 발생하는 독특한 피이크가 있는 X-선 분말 회절 패턴 및 3370, 1670, 1525, 1490, 1280, 890, 870 및 500㎝-1에서 예리한 피이크가 있는 적외선 스펙트럼 (KBr에서0.5%)을 갖고, 결정형이고 다른 물리적 형태가 실제적으로 없는 N-[4-[5-(시클로펜틸옥시카르보닐)-아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 물리적 형태.
  2. 뜨거운 아세톤 수용액에서 N-[4-[5-(시클로펜틸옥시카르보닐)-아미노-1-메틸-인돌-3-일메틸]-2-메톡시벤조일]-2-메틸벤젠술폰아미드의 소오스를 용해시키고, 결과의 용액의 체적을 증발에 의해 감소시키고, 톨루엔을 부가하고, 그 체적을 증발에 의해 더욱 더 감소시키는 것을 포함하는, 제1항의 N-[4-[5-(시클로펜틸옥시카르보닐)-아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 물리적 형태의 제조방법.
  3. 제1항의 N-[4-[5-(시클로펜틸옥시카르보닐)-아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 물리적 형태와 제약학적으로 허용가능한 포사약을 포함하는 제약 조성물.
  4. 제3항에 있어서, 계측 투압 흡입기에 의해 투여하기에 적당하고, 제약학적으로 허용 가능한 포사약을 포함하는 제약 조성물.
  5. 제4항에 있어서, 포사약이 트리클로로플루오로메탄, 디클로로디플루오로메탄, 디클로로 테트라플루오로에탄 또는 1,1,1,2-테트라플루오로에탄을 포함하는 조성물.
  6. 다른 물리적 형태가 실제적으로 없는 N-[4-[5-(시클로펜틸옥시카르보닐)-아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 물리적 형태로서, 상기의 물리적 형태는 2θ=8.1, 13.7, 16.4, 20.5 및 23.7°에서 발생하는 독특한 피이크가 있는 X-선 분말 회절 패턴 및 3370, 1670, 1525, 1490, 1280, 890, 870 및 500㎝-1에서 예리한 피이크가 있는 적외선 스펙트럼 (KBr에서 0.5%)을 갖고 결정성이며, 또한 상기의 형태는 최소한 90%가 10미크론이하의 직경을 갖는 입자들의 응집물로 이루어진 연질 펠릿의 형상이며, 상기의 펠릿은 50 내지 900미크론의 직경을 갖는, 상기의 물리적 형태.
  7. 제1항의 N-[4-[5-(시클로펜틸옥시카르보닐)-아미노-1-메틸-인돌-3-일메틸]-3-메톡시벤조일]-2-메틸벤젠술폰아미드의 물리적 형태의 미립자화된 입자를 150 내지 700 미크론의 구경을 갖는 체를 통해 압출하고, 압출된 물질을 로울링한후, 로울링된 물질을 스크리닝는 것을 포함하는, 제6항의 물질의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910022609A 1990-12-12 1991-12-11 헤테로 고리 화합물 KR100194479B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027018A GB9027018D0 (en) 1990-12-12 1990-12-12 Heterocyclic compounds
GB9027018.2 1990-12-12

Publications (2)

Publication Number Publication Date
KR920012031A true KR920012031A (ko) 1992-07-25
KR100194479B1 KR100194479B1 (ko) 1999-06-15

Family

ID=10686919

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910022609A KR100194479B1 (ko) 1990-12-12 1991-12-11 헤테로 고리 화합물

Country Status (28)

Country Link
US (1) US5294636A (ko)
EP (1) EP0490649B1 (ko)
JP (1) JP2650807B2 (ko)
KR (1) KR100194479B1 (ko)
CN (2) CN1032469C (ko)
AP (1) AP286A (ko)
AT (1) ATE145199T1 (ko)
AU (1) AU656344B2 (ko)
CA (1) CA2056067C (ko)
CZ (1) CZ288151B6 (ko)
DE (1) DE69123123T2 (ko)
DK (1) DK0490649T3 (ko)
ES (1) ES2094797T3 (ko)
FI (1) FI101296B (ko)
GB (2) GB9027018D0 (ko)
GR (1) GR3021605T3 (ko)
HK (1) HK81497A (ko)
HU (2) HU213109B (ko)
IE (1) IE914316A1 (ko)
IL (1) IL100090A (ko)
MX (1) MX9102475A (ko)
MY (1) MY108629A (ko)
NZ (1) NZ240940A (ko)
PH (1) PH30041A (ko)
RU (1) RU2107682C1 (ko)
SK (1) SK279018B6 (ko)
TW (1) TW222264B (ko)
ZA (1) ZA919772B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113581T1 (de) * 1990-05-04 1994-11-15 Ciba Geigy Ag Substituierte indole.
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
WO1995009615A1 (en) * 1993-10-01 1995-04-13 Astra Aktiebolag Process i
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
JP2010535234A (ja) * 2007-07-30 2010-11-18 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
WO2018140858A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
AU2022276190A1 (en) 2021-05-19 2024-01-18 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives

Also Published As

Publication number Publication date
GB2250743A (en) 1992-06-17
CS375891A3 (en) 1992-06-17
FI101296B1 (fi) 1998-05-29
IL100090A0 (en) 1992-08-18
GR3021605T3 (en) 1997-02-28
AP9100341A0 (en) 1992-01-31
CN1032469C (zh) 1996-08-07
HU213109B (en) 1997-02-28
JPH04266872A (ja) 1992-09-22
GB2250743B (en) 1995-02-15
CN1074411C (zh) 2001-11-07
FI101296B (fi) 1998-05-29
MY108629A (en) 1996-10-31
ATE145199T1 (de) 1996-11-15
AU8899591A (en) 1992-06-18
AU656344B2 (en) 1995-02-02
CA2056067C (en) 2001-09-04
AP286A (en) 1993-09-26
FI915825A (fi) 1992-06-13
RU2107682C1 (ru) 1998-03-27
EP0490649A1 (en) 1992-06-17
HK81497A (en) 1997-06-27
DK0490649T3 (da) 1997-04-21
ES2094797T3 (es) 1997-02-01
CN1063100A (zh) 1992-07-29
ZA919772B (en) 1992-09-30
CN1148491A (zh) 1997-04-30
IL100090A (en) 1996-09-12
GB9126353D0 (en) 1992-02-12
CA2056067A1 (en) 1992-06-13
HU211125A9 (en) 1995-10-30
PH30041A (en) 1996-11-08
KR100194479B1 (ko) 1999-06-15
FI915825A0 (fi) 1991-12-11
HUT60717A (en) 1992-10-28
TW222264B (ko) 1994-04-11
NZ240940A (en) 1994-05-26
IE914316A1 (en) 1992-06-17
SK279018B6 (sk) 1998-05-06
EP0490649B1 (en) 1996-11-13
DE69123123D1 (de) 1996-12-19
JP2650807B2 (ja) 1997-09-10
HU913863D0 (en) 1992-02-28
MX9102475A (es) 1992-06-01
DE69123123T2 (de) 1997-03-06
US5294636A (en) 1994-03-15
CZ288151B6 (en) 2001-05-16
GB9027018D0 (en) 1991-01-30

Similar Documents

Publication Publication Date Title
KR920012031A (ko) 헤테로고리 화합물
US3133863A (en) Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
KR840000226A (ko) 신규한 형태의 의약품의 제조방법
KR910004180A (ko) 저작성 약제학적 정제를 제조하기 위한 회전과립화 공정 및 맛을 은폐하기 위한 피복공정
JPS63162627A (ja) 徐放性医薬製剤
PT89823B (pt) Processo para a preparacao de um granulado farmaceutico com propriedades de fluidez melhoradas
EP0525389A3 (en) Process for preparing mechanically stable, well disintegrating tablets from small active agent containing solid forms
DE69530759T2 (de) Filmbeschichtete tablette, die paracetamol und domperidone enthält
NO20002831L (no) Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette
FR2636628B1 (fr) Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
KR880004803A (ko) 분무 건조된 아세트아미노펜
IL49205A0 (en) A4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole derivative,its production and pharmaceutical compositions containing it
ATE219942T1 (de) Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
KR880004805A (ko) 분무건조된 아세트아미노펜
DE1068863B (ko)
JPS5420126A (en) Pharmaceutical composition
Herman et al. Instability of drug release from anhydrous theophylline-imcrocrystalline cellulose formulations
DE60104442T2 (de) Neue galenische dispergierbare und lösliche paracetamol-zubereitung, methode zu deren herstellung und deren anwendungen
US3493659A (en) Compositions and process for the production thereof
JPS5726615A (en) Improving method for absorbability of slightly soluble drug
JP3776941B2 (ja) 味覚の改善された顆粒剤及びその製造方法
KR100358614B1 (ko) 푸시드산정제의제조방법
ES2056254T3 (es) Procedimiento para la fabricacion de un producto instantaneo granulado conteniendo almidon.
JPH04300821A (ja) 被覆製剤
BE826711A (fr) Derives d'indolylacetylamino-acide, leur procede de preparation et les compositions pharmaceutiques contenant ces composes

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050107

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee